Celltrion "Remsima SC Receives Recommendation for IBD-Related Sales Approval in Europe"
[Asia Economy Reporter Minji Lee] Celltrion announced on the 29th that it has obtained a unanimous recommendation for marketing approval targeting 31 European countries from the Committee for Medicinal Products for Human Use under the European Medicines Agency for indications related to inflammatory bowel disease (IBD). The indications for this drug include IBD, adult Crohn's disease, adult ulcerative colitis, psoriatic arthritis, and psoriasis.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- Jensen Huang: "China Will Eventually Allow Imports of U.S. AI Chips"
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
The company stated, "This recommendation is for additional indications following the marketing approval for rheumatoid arthritis indications in November last year," and added, "If final approval is granted within the third quarter, the drug will be marketed throughout Europe through Celltrion Healthcare."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
